Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
The adverse events caused by botulinum toxin type A (subtype A1) product, thought to be after-effects of toxin diffusion after high-dose administration, have become serious issues. A preparation showing less diffusion in the body than existing drugs has been sought. We have attempted to produce neurotoxin derived from subtype A2 (A2NTX) with an amino acid sequence different from that of neurotoxin derived from subtype A1 (A1NTX). In this study, to investigate whether A2NTX has the potential to resolve these issues, we compared the safety of A2NTX, a progenitor toxin derived from subtype A1 (A1 progenitor toxin) and A1NTX employing the intramuscular lethal dose 50% (im LD50) in mice and rats and the compound muscle action potential (CMAP) in rats. Mouse im LD50 values for A1 progenitor toxin and A2NTX were 93 and 166 U/kg, respectively, and the rat im LD50 values were 117 and 153 U/kg, respectively. In the rat CMAP test, the dose on the contralateral side, which caused a 50% reduction in the CMAP amplitude, that is, CMAP-TD50 , was calculated as 19.0, 16.6 and 28.7 U/kg for A1 progenitor toxin, A1NTX and A2NTX, respectively. The results indicate that A2NTX is safer than A1 progenitor toxin and A1NTX.
The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Kumamoto, Japan; Graduate School of Medicine, Osaka University, Osaka, Japan.
Yasushi
Y
Torii
Yoshitaka
Y
Goto
Shinji
S
Nakahira
Shunji
S
Kozaki
Ryuji
R
Kaji
Akihiro
A
Ginnaga
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000633:toxicity*; D005260:Female; D007839:Functional Laterality / Q000187:drug effects; D007273:Injections, Intramuscular; D007928:Lethal Dose 50; D051379:Mice; D008813:Mice, Inbred ICR; D018482:Muscle, Skeletal / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley
D019274:Botulinum Toxins, Type A